Tag: #oncology11 results
Paris-based startup Raidium has deployed its AI-native imaging platform, Raidium Read, at Moffitt Cancer Center. The platform replaces legacy radiomics applications to support clinical trials and research.
Astellas Pharma is aggressively expanding its CLDN18.2-targeted oncology pipeline through acquisitions and partnerships to maintain its lead in gastric cancer treatment. The market is becoming increasingly competitive with ADC and bispecific antibody developments.
The OPTIMA trial demonstrates that using the Prosigna gene signature test allows low-risk breast cancer patients to safely skip chemotherapy without compromising survival rates. This shift highlights a growing trend in oncology toward 'de-escalation' using biomarker-driven decision making.
Chinese oncologists are increasingly leading international clinical trials and presenting groundbreaking research at major conferences like ASCO, signaling a shift from followers to global leaders in oncology.
Daiichi Sankyo aims to become a top 5 global player in cancer treatment by 2035 via its new mid-term plan. AI will drive 3 trillion yen revenue and 200 billion yen cost cuts. The blueprint details AI's role in this ambitious push.
The article discusses the medical complexities of treating peripheral T-cell lymphoma (AITL) and the role of emerging CAR-T therapies. It highlights that while CAR-T is a promising frontier, it remains an experimental treatment with significant risks.
Roche is aggressively advancing its Ras inhibitor pipeline, aiming to challenge existing market leaders in oncology treatment.
The oncology market is shifting away from traditional PD-1 therapies toward more advanced bispecific and trispecific antibodies. This transition marks a new era in cancer treatment innovation.
China is experiencing a significant shift in oncology trends, with new annual cases exceeding 5 million. This highlights an urgent need for advanced diagnostic and therapeutic solutions.
Novartis has agreed to acquire British biotech firm Myricx Bio to bolster its oncology pipeline. The deal focuses on experimental drug technology designed to target tumors precisely while sparing healthy cells.